OutSee, founded in 2023 and headquartered in the United Kingdom, is carving a niche in the realm of AI genomics. The company is focused on developing advanced computational approaches for genomics, with the primary aim of revolutionizing drug target discovery and precision medicine. Its promising technology leverages artificial intelligence to streamline genomic analysis, providing significant potential for advancements in the medical field.
Recently, OutSee secured a £1.80M Seed investment on 24 June 2025. This round attracted notable investors such as Ahren Innovation Capital, Kadmos Capital, Empirical Ventures, and Panacea Ventures, indicating strong market validation and confidence in the startup's vision. As OutSee continues to innovate, its strategic position in the biotech industry makes it a compelling opportunity for investors seeking exposure to cutting-edge technology in precision medicine.